Latest Genentech Inc. Stories
WASHINGTON, Dec. 30 /PRNewswire-USNewswire/ -- The Coalition for 21st Century Medicine strongly opposes the citizen petition filed by Genentech, Inc. on December 5, 2008, seeking to restrict the ability of laboratories to offer diagnostic tests to physicians and patients.
The next big step in satisfying the computing needs of businesses may come from so-called â€œcloud computing.â€
LAUSANNE, Switzerland, December 4 /PRNewswire/ -- AC Immune SA, a leader in Alzheimer's disease drug development, announced today that the World Economic Forum has elected AC Immune as Technology Pioneer 2009 for its accomplishments as an innovation leader and for its breakthrough technologies that can have a deep impact on business and society. Furthermore, AC Immune released that it has reached significant clinical milestones in the development of innovative therapies against...
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc.
Scientists have reported new clues on how to treat spinal cord and brain injuries.
Genentech, Inc. (NYSE:DNA) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) as a therapy for people with previously treated glioblastoma.
Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc.
NERVIANO, Italy, October 21 /PRNewswire/ -- Nerviano Medical Sciences (NMS), the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced a new multi-year agreement with Genentech, Inc.
Genentech, Inc. (NYSE:DNA) today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin(R) (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned.
- The act of sweetening by admixture of some saccharine substance.